Sarcogent Therapeutics

Sarcogent Therapeutics is a preclinical-stage biotechnology company dedicated to developing gene therapies for rare genetic muscle disorders. The company's core technology focuses on the sarcoglycan complex, a group of proteins essential for maintaining the structural integrity of muscle cell membranes. Sarcogent is advancing a pipeline of adeno-associated virus (AAV) mediated gene replacement therapies designed to treat various forms of Limb-Girdle Muscular Dystrophy (LGMD) caused by sarcoglycan deficiencies. Founded by leading experts from Northwestern University, the company aims to address the significant unmet medical needs of patients with progressive muscle wasting diseases. Their approach involves precise delivery of functional genes to restore the sarcoglycan complex and stabilize muscle fibers. By leveraging deep expertise in muscle biology and genetic medicine, Sarcogent seeks to provide long-term therapeutic benefits for patients with these debilitating conditions.